LSV Asset Management Invests $31.26 Million in Regeneron Pharmaceuticals, Inc. $REGN

LSV Asset Management bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 55,600 shares of the biopharmaceutical company’s stock, valued at approximately $31,262,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Skylands Capital LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter worth approximately $1,161,000. Cibc World Market Inc. increased its position in shares of Regeneron Pharmaceuticals by 232.3% in the third quarter. Cibc World Market Inc. now owns 15,733 shares of the biopharmaceutical company’s stock valued at $8,846,000 after buying an additional 10,999 shares in the last quarter. Caprock Group LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $1,471,000. ING Groep NV lifted its position in shares of Regeneron Pharmaceuticals by 136.0% during the 3rd quarter. ING Groep NV now owns 108,877 shares of the biopharmaceutical company’s stock valued at $61,218,000 after buying an additional 62,749 shares in the last quarter. Finally, Krilogy Financial LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $1,176,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares in the company, valued at $13,860,169.59. This represents a 0.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,636 shares of company stock valued at $2,862,920. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $803.17 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The firm has a market capitalization of $84.41 billion, a PE ratio of 19.33, a PEG ratio of 2.11 and a beta of 0.40. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The firm’s 50-day moving average price is $762.17 and its 200 day moving average price is $665.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business’s revenue was up 2.5% on a year-over-year basis. During the same period last year, the company posted $12.07 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a dividend of $0.94 per share. The ex-dividend date is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.05%.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Oppenheimer reissued an “outperform” rating and issued a $865.00 price target (up previously from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. UBS Group boosted their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Cantor Fitzgerald lifted their price objective on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Finally, Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the stock from $627.00 to $860.00 in a research note on Wednesday, January 7th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $793.81.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.